Vimarsana
Biggest News Aggregation in the World

Page 41 - Neurological Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neurological Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neurological Sciences Today - Breaking & Trending Today

Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021 - Vimarsana News

Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021 Amicus Therapeutics, Inc.January 21, 2021 GMT CRANBURY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that three oral presentations and ten posters highlighting its development programs for Lysosomal Disorders will be included...

Source: apnews.com
Investegate |XBiotech Inc. Announcements | XBiotech Inc.: XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy - Vimarsana News

Investegate |XBiotech Inc. Announcements | XBiotech Inc.: XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy

XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders who specialize in cerebrovascular diseases including ischemic stroke, which is the third leading cause of death and second leading cause of disability in the world. The CMAB...

XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy - Vimarsana News

XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy

XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy AUSTIN, Texas, Jan. 19, 2021 — XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders who specialize in cerebrovascular diseases including ischemic stroke, which is the third leading cause of death and second leading cause of disability in the world. The CMAB is chaired by Clay Johnston, M.D., Ph.D., ...

Medtronic unveils adaptive deep brain stimulation trial in Parkinson's patients - Vimarsana News

Medtronic unveils adaptive deep brain stimulation trial in Parkinson's patients

Medtronic unveils adaptive deep brain stimulation trial in Parkinson's patients Medtronic unveils adaptive deep brain stimulation trial in Parkinson's patients 15 January 2021 | News The randomised study will take place across 12 study sites at leading movement disorders research centers in the US, Europe, and Canada Source: medtronic.com Medtronic plc, the global leader in medical technology, announced the first enrolment in ADAPT-PD (Adaptive DBS Algorithm for Personalised Therapy in Parkinson's Disease), its trial evaluating the safety and efficacy of adaptive deep brain...

Medtronic launches adaptive deep brain stimulation trial in Parkinson's patients - Vimarsana News

Medtronic launches adaptive deep brain stimulation trial in Parkinson's patients

Medtronic unveils adaptive deep brain stimulation trial in Parkinson's patients Medtronic unveils adaptive deep brain stimulation trial in Parkinson's patients 15 January 2021 | News The randomised study will take place across 12 study sites at leading movement disorders research centers in the US, Europe, and Canada Source: medtronic.com Medtronic plc, the global leader in medical technology, announced the first enrolment in ADAPT-PD (Adaptive DBS Algorithm for Personalised Therapy in Parkinson's Disease), its trial evaluating the safety and efficacy of adaptive deep brain...